AbbVie Inc. $ABBV is Laffer Tengler Investments Inc.’s 9th Largest Position

Laffer Tengler Investments Inc. grew its holdings in AbbVie Inc. (NYSE:ABBV) by 4.6% in the third quarter, Holdings Channel.com reports. The institutional investor owned 65,066 shares of the company’s stock after buying an additional 2,868 shares during the quarter. AbbVie makes up 2.4% of Laffer Tengler Investments Inc.’s holdings, making the stock its 9th biggest holding. Laffer Tengler Investments Inc.’s holdings in AbbVie were worth $15,066,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ellenbecker Investment Group grew its position in shares of AbbVie by 0.8% in the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after purchasing an additional 44 shares in the last quarter. Security National Bank of Sioux City Iowa IA lifted its position in AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after buying an additional 45 shares in the last quarter. Matthew Goff Investment Advisor LLC boosted its stake in AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after buying an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC grew its holdings in AbbVie by 2.2% in the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after buying an additional 45 shares in the last quarter. Finally, Willner & Heller LLC grew its holdings in AbbVie by 0.6% in the 3rd quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after buying an additional 46 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive topline Phase 3 AFFIRM results for risankizumab (SKYRIZI) subcutaneous induction in moderately to severely active Crohn’s disease, showing superiority vs. placebo and no new safety signals — a material clinical win that expands AbbVie’s immunology franchise and supports future uptake. AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn’s Disease
• Positive Sentiment: FDA approval for an oral combination of VENCLEXTA and acalabrutinib in previously untreated CLL adds an approved hematology-oncology option to AbbVie’s portfolio, supporting long-term revenue diversification in oncology. AbbVie’s New Data And Approval Test Growth And Valuation Story
• Positive Sentiment: Planned $380M investment to build two new active pharmaceutical ingredient manufacturing facilities in Illinois signals capacity expansion, vertical integration and potential margin/production benefits over time. Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now?
• Positive Sentiment: Multiple analyst/outlet pieces highlight AbbVie’s attractive dividend yield and steady payout growth, which can support investor demand from income-oriented funds and long-term investors. Why AbbVie Stock May Be the Ultimate Option for Dividend Investors
• Neutral Sentiment: Management will present at the Leerink Partners Global Healthcare Conference (fireside chat on March 10), providing another opportunity for guidance clarity and incremental investor Q&A but not an immediate catalyst. AbbVie to Present at the Leerink Partners Global Healthcare Conference
• Neutral Sentiment: Mentions in industry reports on continuous manufacturing and market trends underscore structural tailwinds for pharma manufacturing efficiency but are longer‑term and indirect for AbbVie’s near-term stock moves. Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players – AbbVie…
• Negative Sentiment: Despite the positive headlines, the stock is down today — likely reflecting short‑term profit-taking and a stretched valuation/PE that makes the name sensitive to market rotation and earnings expectations in the near term.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ABBV shares. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research note on Tuesday, January 20th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Royal Bank Of Canada started coverage on shares of AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target for the company. Finally, Evercore reduced their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $253.15.

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.08% of the stock is currently owned by corporate insiders.

AbbVie Price Performance

ABBV stock opened at $233.44 on Wednesday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a market capitalization of $412.76 billion, a P/E ratio of 98.92, a P/E/G ratio of 0.81 and a beta of 0.34. The business’s 50-day moving average is $224.56 and its two-hundred day moving average is $223.66.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the previous year, the business posted $2.16 EPS. The firm’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.